Targets › CIDEB
1 program from 1 company in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Aug 2027.
Lipid transferase specifically expressed in hepatocytes, which promotes unilocular lipid droplet formation by mediating lipid droplet fusion. Lipid droplet fusion promotes their enlargement, restricting lipolysis and favoring lipid storage. (UniProt, Q9UHD4)
Open in Phaseline: the race on CIDEB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | ALN-CIDEB CIDEB inhibitor | CIDEB | Phase 3 | Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Aug 2027 |
Metabolic Dysfunction-Associated Steatotic Liver Disease (2) Metabolic Dysfunction-Associated Steatohepatitis (MASH) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.